Moxalactam kinetics during continuous ambulatory peritoneal dialysis after intraperitoneal administration. 1985

T E Jones, and R W Milne, and Y Mudaliar, and L N Sansom

Moxalactam kinetics during continuous ambulatory peritoneal dialysis (CAPD) was followed in eight patients after a single intraperitoneal dose of 1 g. Approximately 60% of the dose was absorbed after a dwell time of 4 h. Dialysis solutions were exchanged at 4-h intervals with an overnight dwell of 8 h. The mean (+/- standard deviation) elimination half-life was 13.2 +/- 2.9 h, and the mean apparent volume of distribution was 0.22 +/- 0.08 liters/kg. Mean total clearance was 11.5 +/- 2.4 ml/min, with a mean dialysis clearance of 2.3 +/- 0.5 ml/min. The maximum concentration in plasma ranged from 24.5 to 54.1 micrograms/ml. Moxalactam concentrations in the peritoneal dialysis fluid were above 80 micrograms/ml during the first exchange and above 2 micrograms/ml for a further three exchanges. A suggested intraperitoneal dose regimen for patients undergoing CAPD is 1 g initially, followed by 15 to 25% of the recommended dose for normal patients given at the same time intervals, or 30 to 50% of the recommended dose at twice the usual intervals. Moxalactam is suggested for initial treatment of peritonitis in CAPD patients who do not have ready access to the antibiotic of choice.

UI MeSH Term Description Entries
D007274 Injections, Intraperitoneal Forceful administration into the peritoneal cavity of liquid medication, nutrient, or other fluid through a hollow needle piercing the abdominal wall. Intraperitoneal Injections,Injection, Intraperitoneal,Intraperitoneal Injection
D007700 Kinetics The rate dynamics in chemical or physical systems.
D008297 Male Males
D008657 Metabolic Clearance Rate Volume of biological fluid completely cleared of drug metabolites as measured in unit time. Elimination occurs as a result of metabolic processes in the kidney, liver, saliva, sweat, intestine, heart, brain, or other site. Total Body Clearance Rate,Clearance Rate, Metabolic,Clearance Rates, Metabolic,Metabolic Clearance Rates,Rate, Metabolic Clearance,Rates, Metabolic Clearance
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009070 Moxalactam Broad- spectrum beta-lactam antibiotic similar in structure to the CEPHALOSPORINS except for the substitution of an oxaazabicyclo moiety for the thiaazabicyclo moiety of certain CEPHALOSPORINS. It has been proposed especially for the meningitides because it passes the blood-brain barrier and for anaerobic infections. 1-Oxacephalosporin,6059-S,Disodium Latamoxef,Disodium Moxalactam,Festamoxin,Lamoxactam,Latamoxef,Lilly 127935,Ly-127935,Ly127935,Moxalactam Disodium,S-6059,Shiomarin,1 Oxacephalosporin,6059 S,6059S,Disodium, Moxalactam,Latamoxef, Disodium,Ly 127935,Moxalactam, Disodium,S 6059,S6059
D010531 Peritoneal Dialysis, Continuous Ambulatory Portable peritoneal dialysis using the continuous (24 hours a day, 7 days a week) presence of peritoneal dialysis solution in the peritoneal cavity except for periods of drainage and instillation of fresh solution. CAPD,Continuous Ambulatory Peritoneal Dialysis
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

T E Jones, and R W Milne, and Y Mudaliar, and L N Sansom
September 1983, Clinical pharmacology and therapeutics,
T E Jones, and R W Milne, and Y Mudaliar, and L N Sansom
February 1984, Clinical pharmacology and therapeutics,
T E Jones, and R W Milne, and Y Mudaliar, and L N Sansom
January 1986, European journal of clinical pharmacology,
T E Jones, and R W Milne, and Y Mudaliar, and L N Sansom
July 1983, Clinical pharmacology and therapeutics,
T E Jones, and R W Milne, and Y Mudaliar, and L N Sansom
November 1983, Clinical pharmacology and therapeutics,
T E Jones, and R W Milne, and Y Mudaliar, and L N Sansom
June 1987, Chemioterapia : international journal of the Mediterranean Society of Chemotherapy,
T E Jones, and R W Milne, and Y Mudaliar, and L N Sansom
December 1985, American heart journal,
T E Jones, and R W Milne, and Y Mudaliar, and L N Sansom
January 1984, Presse medicale (Paris, France : 1983),
T E Jones, and R W Milne, and Y Mudaliar, and L N Sansom
June 1986, Drug intelligence & clinical pharmacy,
T E Jones, and R W Milne, and Y Mudaliar, and L N Sansom
November 1990, Journal of clinical pharmacology,
Copied contents to your clipboard!